Research progress on prognostic factors of primary central nervous system lymphoma
10.13303/j.cjbt.issn.1004-549x.2021.04.028
- VernacularTitle:原发中枢神经系统淋巴瘤预后因素研究进展
- Author:
Shuoting WANG
1
;
Jie GAO
1
;
Qianqing SHEN
1
;
Yongqian JIA
1
Author Information
1. Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, China
- Publication Type:Journal Article
- Keywords:
PCNSL;
prognostic factor;
microRNA;
ctDNA
- From:
Chinese Journal of Blood Transfusion
2021;34(4):428-431
- CountryChina
- Language:Chinese
-
Abstract:
Primary central nervous system lymphoma (PCNSL) is a rare and special kind of non-Hodgkin lymphoma. Chemotherapy based on high-dose methotrexate (HD-MTX) is considered a standard therapy for newly diagnosed PCNSL, but the prognosis of PCNSL is poor due to its high invasiveness and recurrence rate. Risk stratification and prognosis assessment of PCNSL in diagnosis is particularly important in clinical treatment. At present, MSKCC (the Memorial Sloan Kettering Cancer Center), the International Extranodal Lymphoma Study Group (IELSG) and Nottingham/Barcelona scoring models are mostly used to classify the risk and evaluate the prognosis of PCNSL. With the further understanding of immunohistochemistry and molecular genetics of PCNSL, potential prognostic factors continue to emerge.
